U.S. markets open in 42 minutes
  • S&P Futures

    4,520.50
    -7.50 (-0.17%)
     
  • Dow Futures

    35,428.00
    -49.00 (-0.14%)
     
  • Nasdaq Futures

    15,344.25
    -33.25 (-0.22%)
     
  • Russell 2000 Futures

    2,285.80
    -1.70 (-0.07%)
     
  • Crude Oil

    83.08
    -0.34 (-0.41%)
     
  • Gold

    1,783.70
    -1.20 (-0.07%)
     
  • Silver

    24.33
    -0.11 (-0.45%)
     
  • EUR/USD

    1.1655
    +0.0003 (+0.02%)
     
  • 10-Yr Bond

    1.6660
    +0.0300 (+1.83%)
     
  • Vix

    15.91
    +0.21 (+1.34%)
     
  • GBP/USD

    1.3817
    -0.0009 (-0.06%)
     
  • USD/JPY

    114.0060
    -0.3230 (-0.28%)
     
  • BTC-USD

    65,022.57
    +674.87 (+1.05%)
     
  • CMC Crypto 200

    1,537.35
    +56.54 (+3.82%)
     
  • FTSE 100

    7,191.62
    -31.48 (-0.44%)
     
  • Nikkei 225

    28,708.58
    -546.97 (-1.87%)
     

CytRx presents aldoxorubicin Phase 2b trial data

CytRx announced that Phase 2b trial data comparing first-line treatment with aldoxorubicin has been selected for oral presentation at the 2014 American Society for Clinical Oncology Annual Meeting. Aldoxorubicin is currently being studied in a pivotal, global Phase 3 clinical trial evaluating the efficacy and safety of aldoxorubicin as a second-line treatment for patients with STS under a Special Protocol Assessment with the FDA. CytRx is also conducting two Phase 2 clinical trials evaluating aldoxorubicin in patients with late-stage glioblastoma and HIV-related Kaposi’s sarcoma.